Detta innehåll är avsett för vårdpersonal

Till innehåll för allmänhet

Inbjudan till webinaret "ECIL-10 CMV guidelines and what has happened since then"

Bild
CMV-virus

Let’s Talk CMV and Beyond 2026

We invite you to engaging sessions covering key updates on the International Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation, ECILs guidelines and patient cases.

Join us for an interactive Nordic meeting.
We invite you to an engaging session covering the topic: ”ECIL-10 CMV guidelines and what has happened since then”.
This is a unique opportunity to engage with leading experts, gain valuable insights, and participate in dynamic discussions.


Time: March 18th, 2026, 16.30 -17.30 (CET), 17.30 -18.30 Finnish time
Place: Webinar


AGENDA 18th of March

 

16.30–16.35 Welcome by Takeda  
16.35–17.05 ECIL-10 CMV guidelines and
what has happened since then.
Per Ljungman
17.05–17.20 Patient case Marietta Nygaard
17.20–17.30 Q&A  
17.30 Closing remarks by Takeda

 

 

SPEAKER

Per Ljungman, Prof. Emeritus, Karolinska Institutet
Marietta Nygaard, Dr, department of hematology, Rigshospitalet Copenhagen

REGISTER TO MEETING

For more information and registration for
webinar on 18th of March, please click here
Please register before 13th of March 2026

 

VÄLKOMMEN

 

Emma Silfverswärd
Brand and Customer Manager
M: +46 705 216 373
emma.silfversward@takeda.com

Birgitta Trangius
Key Account Manager
Immunology
M: +46 70-552 13 55
birgitta.trangius@takeda.com

Christina Kristensson
Key Account Manager
Immunology
M: +46 73-840 82 48
christina.kristensson@takeda.com

 

This meeting is initiated, organized and funded by Takeda. Takeda covers, in accordance with LER, speaker fees within the framework of the meeting. Participation in the meeting is free of charge. According to the agreement on information and education between the Swedish Association of the Pharmaceutical Industry (Läkemedelsindustriföreningen) and SKL, this invitation to the training has been sent as a copy to your operations manager as well as the relevant pharmaceutical committee. The mailing has been sent using information from the Healthcare Address Register (HSAR) by Takeda Pharma AB, which is affiliated with the HSAR Data Protection Program. Further information about address details and registration can be obtained via www.hsar.se or from IQVIA, +46 8-555 214 20.
C-ANPROM/SE/CMV/0007 02/2026